Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma After Frontline Transplant: A Multicenter, Randomized, Phase 3 Study (AURIGA)

Autor:	Ming Qi, Ryan Krey, Christopher Chiu, Maria Krevvata, Yana Lutska, Katherine Ryland, Thomas S. Lin, Huiling Pei, Colleen Kane, Jon Ukropec, Shalaka S. Hampras, Nina Shah
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Daratumumab Phases of clinical research Hematology Newly diagnosed medicine.disease Internal medicine medicine In patient business Multiple myeloma Lenalidomide medicine.drug
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 19:e199
ISSN:	2152-2650
DOI:	10.1016/j.clml.2019.09.332
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2ebc87c964e5b30fe3e6d0206c354f1f https://doi.org/10.1016/j.clml.2019.09.332 Zobrazit plný text záznamu Full Text from ScienceDirect